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Pediatric cardiologyThe metabolome is the complete set of metabolites found in a biological cell, tissue, organ or organism,
representing the end products of cellular processes. Metabolomics is the systematic study of small-moleculeme-
tabolite proﬁles produced by speciﬁc cellular processes. mRNA gene expression data and proteomic analyses do
not show the complexity of physiopathological processes that occur in a cell, tissue or organism. Metabolic pro-
ﬁling, in contrast, represents a paradigm shift in medical research from approaches that focus on a limited num-
ber of enzymatic reactions or single pathways, with the goal of capturing the complexity of metabolic networks.
In this article, we will provide a description of metabolomics in comparison with other, better known “omics”
disciplines such as genomics and proteomics. In addition, we will review the current rationale for the implemen-
tation of metabolomics in cardiology, its basic methodology and the available data from human studies in this
discipline. The topics covered will delineate the importance of being able to use the metabolomic information
to understand the mechanisms of diseases from the perspective of systems biology, and as a non-invasive
approach to the diagnosis, grading and treatment of cardiovascular diseases.
© 2015 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The “omics” sciences refer to a group of analytical methodologies
that aim to achieve the collective characterization and quantiﬁcation
of pools of biological molecules, such as genes, transcripts, proteins
and metabolites, which translate into the structure, function and
dynamics of cells, tissues or organisms. Genomics can be described as
a comprehensive analysis of DNA structure and function [1]. Under-
standing biological diversity at the whole genome level will provide
insight into the origins of individual traits and disease susceptibility.
Proteomics involves the systematic study of proteins to provide a com-
prehensive view of the structure, function and regulation of biological
systems [2]. Genomics not only involves the study of single-nucleotide
polymorphisms (SNP) and mutations in DNA, but it also includes,
through the sub-discipline of transcriptomics, the complete analysis of
gene expression in a cell. However, mRNA gene expression data and
proteomics analyses do not show the complexity of the physiological
and/or pathological processes that occur in a cell, tissue or organism. In
contrast, the metabolomic approach represents a paradigm revolutionences “M. Aresu”, University of
, Monserrato, 09042 Cagliari,
and Ltd. This is an open access articlein medical research, from a perspective that focuses on single pathways
towards a holistic investigation that is able to capture the complexity of
entire metabolic networks [3,4]. See Fig. 1
Metabolomics (or metabonomics) is the study of the metabolic pro-
ﬁle of small molecules in a biological organism. The metabolome, in
turn, is deﬁned as the complete set of metabolites present in a cell, tis-
sue, organ or organism [5] and represents all of the end products of cel-
lular processes [3,4]. Metabolomics provides a functional view of an
organism, as determined by the sum of its genes, RNA, proteins, and en-
vironmental factors including, for example, nutrition, medications and
treatments. It reﬂects the true functional endpoints of biological events
and is extensively used as a “functional-genomic” tool and in systems
biology [3,4]. The philosophy underlying functional genomics is that a
given “biologic” event should not be viewed as an isolated phenomenon
but as a part of a complex network of changes, capable to interfere each
other,within anorganism; corollary of this afﬁrmation is that in order to
understand a biological event in all its complexity is necessary to mea-
sure as many entities as possible at any level of organization [3]. Specif-
ically, metabolomics is the study of “… the complete set of metabolites/
low-molecular-weight intermediates, which are context dependent,
varying according to the physiology, developmental or pathological
state of the cell, tissue, organ or organism…”, while metabonomics
has been deﬁned as the “quantitative measurement of the dynamic
multiparametric metabolic response of living systems to pathophysio-
logical stimuli or genetic modiﬁcation”, [6–8]. These two terms areunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. From gene expression to phenotype. What “omics” tell us and how they interact.
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Fig. 2). In this paper, we prefer to use the term metabolomics to refer
to either of the aforementioned meanings.
1.1. General aspects
As mentioned above, metabolomics is the measurement of multiple
small-molecule metabolites in biological samples, including body ﬂuids
(urine, blood, cerebrospinal ﬂuid, saliva, among others), tissues (heart,
liver, kidney, brain, among others) and exhaled breath [9]. This technol-
ogy is able to provide a comprehensive proﬁle of the metabolic state of
thewhole organism, and it is linked to genetic settings and the inﬂuence
of endogenous (i.e., hormones) and exogenous (i.e., food, drugs) sub-
stances or pathophysiological conditions. These stimuli induce a series
of biochemical reactions that generate a wide and complex array of me-
tabolites, many of which will be released in body ﬂuids and tissues.
Metabolomic analytical technologies can identifymoleculeswith a rela-
tively low molecular weight (b1000 Da), including amino and fatty
acids, nucleic acids, carbohydrates, organic acids, vitamins, polyphenols,
lipids, intermediates of many biochemical pathways, and inorganic and
elemental species. The analysis of human biological samples provides
characteristic numbers of metabolites, depending on the bioﬂuid or
tissue under examination and the analytical instrumentation used,
and they can reach values in the thousands. The Human Metabolome
Project [10], that has the aim to identify, quantify, catalog and record
all metabolites potentially found in human specimens, have alreadyFig. 2. The increasing number of publications covering the following search terms:
Metabolomic* or Metabonomic*.identiﬁed over 40,000 metabolites, stored in the Human Metabolome
Database [11].
The metabolomic approach consists of two sequential steps:
• The sample is analyzed using an experimental technique that is
suitable for providing a detailed molecular ﬁngerprint, i.e., the
full complement of low-molecular-weight metabolites; and
2) the data analysis is performed to identify and quantify the cor-
relation between the identiﬁed species and the metabolic pro-
cesses under investigation.
1.2. Experimental techniques
Amongmany different technological platforms, such as infrared and
ﬂuorescence spectroscopy and Coulombic arrays, nuclear magnetic res-
onance (NMR) spectroscopy and mass spectrometry (MS) have been
successfully used in themetabolomicsﬁeld (Table 1), but themost com-
monly used are certainly the last two [3]. The NMR technique provides a
detailed molecular picture of the biological sample. It simultaneously
detects, in a non-targeted manner, signals from many different com-
pounds, such as carbohydrates, amino acids, organic and fatty acids,
amines, and lipids, without any initial sample pretreatment. In the
NMR spectrum (See Fig. 3), each metabolite generates its own speciﬁc
signals (often referred to as resonances). Each resonance displays a
ﬁne structure that can be directly related to the relative position of the
different chemical groups in the chemical structure of the metabolite.
The resonance intensity is proportional to the number of nuclei under
observation generating that speciﬁc resonance, and to the molar con-
centration of the metabolite. Mass spectrometry, which is typically
combinedwith a high-resolution separation technique like gas chroma-
tography (GC) or liquid chromatography (LC), discriminates the mole-
cules present in a biological sample according to their mass-to-charge
ratio. Each of the peaks in the resulting chromatogram is associated
with the characteristic mass spectrum of the metabolite (See Fig. 4),
allowing their identiﬁcation. NMR and MS have different advantages
and limitations, and they are often regarded as complementary tech-
niques. NMR provides a relatively fast but detailed analysis of the mo-
lecular composition of the sample with a (usually) rather simple
preparation. The experiments are highly reproducible; the technique
is non-destructive and represents a universal detector for all of themol-
ecules containing NMR-active nuclei. However, NMR spectroscopy has
somemajor drawbacks,mainly concerning the relatively low sensitivity
when compared to other analytical techniques and the high manage-
ment costs. On the other hand, MS techniques are highly speciﬁc and
Table 1
Technique of analysis used in Metabolomics (modiﬁed from Grifﬁn et al. [3]).
Techique Cost Throughput Advantages Disadvantages
High-resolution NMR
spectroscopy
Low per
sample
~10 min Simultaneous detection of many different compounds,
such as carbohydrates, amino acids, organic and fatty
acids, amines, and lipids without any initial sample
pre-treatment
Technique non-destructive
Good libraries of spectra
Easy to process
Poor sensitivity
Co-resonances for 1D-NMR spectroscopy
2D-NMR spectroscopy is time consuming
In vivo NMR spectroscopy High ~30 min with
preparation time
Possibility to observe metabolism of the working heart
Imaging can map metabolite distributions
Very poor sensitivity (hyperpolarization or
higher ﬁeld strengths could improve it)
High-resolution magic-angle-
spinning NMR
Low ~15 min Possibility to monitor cellular environment (e. g.,
compartmentation) in intact tissue
Tissue can be chilled to reduce post- mortem effects
Tissue cannot be perfused, so their viability
is limited
Direct-infusion MS Low 3–4 min Has been used to proﬁle both aqueous
and lipophilic metabolites in various studies
Minimal carry-over, as no chromatography involved
Good reproducibility
Simple to optimize
Ion suppression can be a substantial
problem Identiﬁcation can require
chromatography,
e. g. for isobaric species
Metabolite identiﬁcation is a major
challenge and requires MSn acquisitions
Semiquantitative at best
GC–MS Low–medium 20–30 min for fatty
acids
30–45 min for aqueous
metabolites
Chromatography is robust and reproducible
Metabolite identiﬁcation is aided by adoption of
common ionization parameters in electron impact and
wide availability of the
Can be quantitative
Metabolites need derivatization and not all
metabolites are suitable for derivatization
LC–MS Medium ~15–30 min Chromatography reduces the effect of ion suppression
and can separate isobaric species
Suitable for measuring intact lipids, dipeptides,
tripeptides, and other macromolecules
Chromatography can drift during a sample
run, which makes data processing difﬁcult
Metabolite identiﬁcation is a major
challenge
Triple–quadrupole (targeted)
MS
Medium
to high,
15 min per
chromatography run
~60 min for more
comprehensive screens
Highly sensitive
Highly quantitative
Targeted
Results readily transferable because concentrations
can be measured
Targeted, so discovery of novel biomarkers
unlikely
Time consuming to set up quantitative
assays
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(i.e., derivatization), which implies the consumption of specimens.1.3. Data analysis and interpretation
In metabolomic studies, different approaches are used for the collec-
tion, processing and interpretation of the data depending on the speciﬁc
problem: metabolic proﬁling, metabolomics and metabolic ﬁngerprint-
ing.Metabolic proﬁling seeks to identify and quantify a selected number
of pre-deﬁned metabolites in a given sample, whereas metabolomics
allows the complete analysis of all of the metabolites in a sample,
which are quantiﬁed and identiﬁed (targeted analyses). Finally, meta-
bolic ﬁngerprinting is aimed at measuring the global proﬁle of the
metabolites characterizing the sample, without speciﬁc identiﬁcation
and quantiﬁcation (untargeted analyses).
In the metabolomics ﬁeld, many hundreds of samples are routinely
analyzed, and aminimumof several hundreds ofmetabolites are usually
detected. However, the detection of metabolites, in the case of biologicalFig. 3. NMR spectrasamples, is not the ﬁnal step; all the data obtained from the collection
stage should be further analyzed using statistical multivariate methods
(chemometrics) to extract biological, physiological and clinically relevant
information. Before performing the statistical analysis, the data are sub-
jected to several processing steps: 1) the spectrum requires different pro-
cessing depending on the speciﬁc analytical techniques employed; 2) a
data matrix is produced from the analytical measurements with m rows
(observations, samples) andn columns (variables, frequencies, integrals);
3) data normalization and scaling are performed; and 4)multivariate sta-
tistical modeling of the data is completed.1.4. Statistical multivariate analysis
In metabolomic studies, the complexity of the spectroscopic data due
to the commonly high number of samples and variables (i.e., metabolites)
inevitably requires the use of data reduction techniques to extract latent
metabolic information and enable sample classiﬁcation and biomarker
identiﬁcation. The statistical multivariate methods can be distinguishedof a HF patient.
Fig. 4.MS spectra of alanine.
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unsupervised method is principal component analysis (PCA), which pro-
vides an initial overview of all of the data for the detection of outliers,
trends, patterns, or clusters. However, the supervised approaches include
the partial least squares discriminant analysis (PLS-DA) or orthogonal
partial least squares discriminant analysis (OPLS-DA), for instance,
which classify samples into different categories or classes based on a
priori knowledge. This a priori information, e.g., the object membership,
constitutes an additional data table, Y, which describes different sample
properties that can be either discrete or continuous to be used together
with the experimental data table, X, within the multivariate analysis.
The N-dimensional results are typically presented as easier to read two-
dimensional (2D) projections. One of these is referred to as the scores
plot, which reveals any inherent clustering of data, trends or outliers.
The other is referred to as the loadings plot, which shows the importance
(weight) of the different variables (i.e., the metabolites) in deﬁning the
model.
1.5. Metabolomics in cardiology
During the last decade, both animal and human studies have facili-
tated the rapid development of metabolomics, and a combination of
targeted anduntargeted approaches has been applied for cardiovascular
research [12]. Speciﬁc metabolic proﬁles have been identiﬁed for sever-
al cardiovascular risk factors and diseases, such as lipid disorders, diabe-
tes, hypertension, myocardial ischemia and heart failure [13–19].
Selected human studies are discussed in the following sections.
1.5.1. Metabolic disorders related to cardiovascular risk: obesity,
dyslipidemia and diabetes
Glucose homeostasis is a complex physiologic process involving
multiple organ systems and is strictly related to lipid metabolism/stor-
age. Alterations in glucose and lipid metabolism interfere each other
and have important effects on body composition and all these are able
to modify the CV risk proﬁle.
The spectrum of biochemical changes associated with the transition
from normal glucose homeostasis to insulin resistance and diabetes is
largely unknown. An approach based onMS to simultaneously measure
191 metabolites has been used to study the insulin-dependent homeo-
static program triggered by the ingestion of glucose [20]. In healthy
subjects, the dynamics of themetabolites revealed the actions of insulin
along fourmain axes - proteolysis, lipolysis, ketogenesis and glycolysis -
reﬂecting the transition from catabolism to anabolism. In pre-diabetics,
a blunt response, which correlatedwith insulin resistance in all four axes,
was observed. In details, a decline in glycerol and leucine/iso-leucine
(markers of lipolysis and proteolysis, respectively) was found and
seems to be the strongest predictor of insulin sensitivity. Authorsconcluded that different axes could be responsible for the same elevation
of fasting insulin and that exist two forms of insulin resistance: in
one form, subjects are selectively resistant to insulin's suppression of
proteolysis whereas in the other to insulin's suppression of lipolysis.
On the other hand, genetic, environmental and lifestyle factors are
involved in the etiology of glucose metabolism alterations such as of
obesity. Obesity, for its part, is capable to increase the risk of cardiovas-
cular diseases and diabetes. Pietilainen and coll. carried out ametabolo-
mics investigation on young adult monozygotic twin pairs, discordant
or concordant for obesity, by means of liquid chromatography coupled
to mass spectrometry. The earliest stage of acquired obesity, indepen-
dent of genetic inﬂuences, was found to be primarily associated
with an increase in lysophosphatidylcholines, lipids found in pro-
inﬂammatory and pro-atherogenic conditions, and with a decrease in
ether phospholipids, which are known to have antioxidant properties.
Moreover, these lipid changeswere associatedwith insulin resistance [21].
Changes in lipid metabolism affect CV risk and several clinical trials
[22–24] have demonstrated the beneﬁcial effects of statin treatment in
primary and secondary prevention of CV diseases. A lipidomic analyses
of variation in response to simvastatin conducted on plasma samples of
944 subjects selected form the cholesterol and pharmacogenetics study
revealed a correlation of baseline cholesterol esters and phospholipid
metabolites with the response to treatment of low-density-lipoprotein
cholesterol (LDL) [25]. In addition, the response of C-reactive protein
(CRP) to therapy correlated with basal plasmalogens, which are lipids
that are involved in inﬂammation. This modulation appeared to be in-
dependent of the variation in plasma lipid levels, which correlated
with the LDL-C and CRP responses, thus suggesting that distinct meta-
bolic pathways regulate the effects of statins on these two biomarkers.
Metabolomics has also been applied to the evaluation of metabolic
changes induced by rosiglitazone, which is currently under investiga-
tion due to its adverse effects on cardiovascular outcomes, in type 2
diabetic patients with coronary artery disease (CAD). Badeau and coll.
showed that short-term treatment with rosiglitazone resulted in
minor improvements in metabolism: serum lactate and glutamine con-
centrations changed, reﬂecting improvements in insulin sensitivity, and
circulating lactate concentrations proved to be inversely correlatedwith
the increase in myocardial glucose uptake [26].
More recently, Hung and coll. used a metabolomics approach in
order to evaluate whether plasma metabolic proﬁle during the oral
glucose tolerance test (OGTT) could improve the diagnosis of CAD in pa-
tients with positive non-invasive stress tests. The study was conducted
on 117 subjects with positive stress test results who received coronary
angiography; plasma samples obtained in fasting, 30 min, and 120 min
after OGTT were analyzed using liquid chromatography combined with
mass spectrometry. Results showed that the fasting plasma metabo-
lome, but not its changes during the oral glucose tolerance test, could
improve the diagnosis of CAD in this setting of patients, regardless of
the clinical risk factors [27]. Noteworthy, authors suggested that
tryptophanmetabolism, particularly about indolelactic acid and glutaric
acid, may have a causal relationship with the development of
atherosclerosis.
1.5.2. Hypertension
Hypertension is a major risk factor for CV disease, stroke, and renal
failure and its pathogenesis is signiﬁcantly inﬂuenced by genetic, life-
style, and environmental factors; however, the underlying pathways
remain still to be completely clariﬁed.
On these bases, a GC_MS-based metabolomics study was re-
cently conducted using plasma samples from 20 young hyperten-
sive men and 20 age-matched healthy controls. The authors
discovered a distinct metabolic ﬁngerprint of young patients that
was strongly related to amino acid biosynthesis. The correlations
of GC-MS metabolomics data were visualized as networks based
on Pearson's correlation coefﬁcient (threshold = 0.6), and the var-
iation of several amino acids – glycine, lysine and cysteine –,
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metabolic change in young hypertensive men, thus suggesting that
disorders in amino acid metabolism could play an important role in
the development of hypertension [28].
In line with these data seems to be the results of an NMR study con-
ducted between 2009 and 2012 on 157 hypertensive patients and 99
healthy subjects, all of whom were Uygur people, one of the 55 ethnic
minorities of the People's Republic of China. The recruitment criteria
were systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic
blood pressure (DBP) ≥90mmHgat rest; patientswith secondaryhyper-
tension and previous cardiovascular diseases were excluded from the
study. NMR data/metabolic information were analyzed with PCA, PLS-DA
and OPLS-DA. The OPLS-DA results indicated that the metabolic ﬁnger-
prints were signiﬁcantly different between the two groups, and 12 differ-
ent metabolites were identiﬁed. In comparison with healthy subjects,
hypertensive patients showed lower levels of several amino acids, includ-
ing valine, alanine, pyroracemic acid, inose, p-hydroxyphenylalanine, and
methylhistidine, with a signiﬁcant increase in VLDL, LDL-C, lactic acid,
and acetone. However, a possible limitation of this study could be
that, although clinical data did not show signiﬁcant differences between
the two groups with respect to age, weight, height and some lipid indi-
ces including triglycerides and LDL-C, fasting plasma glucose (FPG), SBP
and DBP, HDL and total cholesterol (TC) were signiﬁcantly different
[29]; basal differences in FPG,HDL and TC levels could have been related
per se to metabolic alterations, leading to a potential misinterpretation
of the observed clustering and/or of the metabolic ﬁngerprint.
Another study targeted to investigate the molecular basis of hyper-
tension was conducted in 2013 by Zheng and coll. They designed
a study aimed to evaluate human serum metabolome before the
onset of hypertension in a well-deﬁned prospective cohort setting.
Metabolomic analysis was performed on serum of 896 black normoten-
sive people from the Atherosclerosis Risk in Communities Study (565
women aged 45–64 years), the blood samples of whom were
collected at the enrollment examination. During a 10-year follow-up,
38% of the baseline normotensive subjects developed hypertension
(n= 344). After adjustment for traditional risk factors and the estimat-
ed glomerular ﬁltration rate, each +1SD difference in baseline
4-hydroxyhippurate, which is a product of gut microbial fermentation,
was associated with a 17% increased risk of hypertension. This correla-
tion remained signiﬁcant after adjusting for both baseline SBP and
DBP. Moreover, the PCA revealed a sex steroid pattern associated with
the risk of incident hypertension that was consistent in both genders
after a stratiﬁed analysis [30].
Metabolomic analysis was also applied in order to verify whether it
waspossible to distinguish between different BP categories based on the
metabolic proﬁle. Sixty-four individuals were classiﬁed into three BP cat-
egories [low/normal (≤130 mmHg), borderline (131–149 mm Hg) and
high systolic BP (SBP; N150 mm Hg)] and studied. After an orthogonal
signal correction of theNMRdata, the PCA scores revealed several similar-
ities in serum metabolic proﬁles between patients in the borderline and
high SBP categories, whereas regions of theNMR spectra attributed to dif-
ferent lipids [in particular, lipoproteins associated with very-low-density
cholesterol (VLDL) and LDL-C] clearly distinguished the borderline/high
BP categories from the low/normal BP category (higher lipid level were
detected in the higher BP categories). However a limitation of this study
was that the enrollment and classiﬁcation of the participants were
based on a single BP measurement taken in a hospital environment, and
thus, there was the potential for misclassiﬁcation of the true BP values
[31].1.5.3. CAD
CAD is one of the prominent causes of morbidity and mortality
worldwide and identiﬁcation of myocardial ischemia is crucial both
for diagnostic aims and for the evaluation of the response to therapeutic
interventions. For these reasons, most of the metabolomic studiescarried out on CADwere addressed to identify biomarkers ofmyocardial
ischemia or to discover possible new diagnostic tools.
In a pioneering clinical application ofmetabolomics, Brindle and coll.
[32] used the pattern-recognition techniques applied to NMR spectra of
human sera to diagnose not only the presence but also the severity of
CAD. The authors argued that in their analysis, N90% of the patients
with stenosis of all three main coronary vessels were distinct from sub-
jects with angiographically normal coronary arteries, with a speciﬁcity
of N90%. The difference between the sample groups, which was mainly
due to subtle changes in lipoprotein composition, supported the poten-
tial of an NMR-based metabolomics approach in predicting the various
stages of CAD. However, Kirschenlohr and coll. later identiﬁed a number
of confounding factors for a diagnosis primarily based on the lipid com-
position; in particular, the use of statins may have biased the results of
the study reported by Brindle [33].
In another study, blood samples were obtained before and after ex-
ercise stress testing from 36 patients, 18 of whom showed inducible is-
chemia (cases) and 18 who did not (controls) [34]. The variations in 6
metabolites, including citric acid, demonstrated a signiﬁcant discordant
regulation between the 2 groups of individuals, differentiating the cases
from controls with a high degree of precision.
In 2008 Barba conducted a similar study on 31 patients with
suspected effort angina without previous myocardial infarction that
underwent a stress single-photon emission computed tomography.
NMR-based metabolomics were able to predict exercise-induced ische-
mia and the main contributors to discrimination were lactate and
glucose, as well as methyl and methylene moieties of lipids and long-
chain amino acids [35].
Progressively, metabolomicswas employed in studieswith design of
increasing complexity, in order to achieve better-controlled experimen-
tal conditions and, then, more accurate results.
In 2008 Lewis examined metabolic proﬁles of individuals undergo-
ing planned or spontaneous myocardial ischemia to identify early bio-
markers of cardiac damage. Thirty-six patients undergoing alcohol
septal ablation treatment for hypertrophic obstructive cardiomyopathy,
a humanmodel of plannedmyocardial infarction (PMI),were examined
and compared with subjects undergoing elective diagnostic coronary
angiography and patients with spontaneous myocardial infarction,
that served as negative and positive controls, respectively; moreover,
coronary sinus sampling was used to discriminate cardiac-derived
from peripheral metabolic changes. A PMI-derived metabolic footprint,
consisting of aconitic acid, hypoxanthine, trimethylamine N-oxide, and
threonine, resulted able to distinguish PMI patients from those under-
going diagnostic coronary angiography with high accuracy and abnor-
malities in circulating metabolites were detected b10 min after
myocardial injury. It is note ofworthy that observedmetabolite changes
are able tomodulate the response to hypoxic injury in vitro, suggesting a
possible role of these metabolites in evolving response to ischemia
in vivo [36].
Another metabolic footprint of acute myocardial ischemia (MIS)
was identiﬁed by Bodi and coll. in a study of 2014, fundamental be-
cause the highly controlled conditions of its design. Investigators
performed an NMR analysis of peripheral blood serum obtained
from swine and patients undergoing angioplasty balloon-induced
transient coronary occlusion [37]. MIS induced 1) an increase in cir-
culating glucose, lactate, glutamine, glycine, glycerol, phenylalanine,
tyrosine, and phosphoethanolamine; 2) a decrease in choline-
containing compounds and triacylglycerols; and 3) a change in the
pattern of total, esteriﬁed, and nonesteriﬁed fatty acids. Moreover,
the authors performed a preliminary clinical validation of the devel-
oped metabolomic biosignature in patients with spontaneous acute
chest pain, achieving a negative predictive value of 95%.
To evaluate the discriminative capabilities ofmetabolites for CAD, an
MS-based proﬁling of 69 metabolites in subjects from the CATHGEN
biorepository was performed by Shah and coll. Two independent case/
control groups were constructed and proﬁled; moreover, cases of both
36 M. Deidda et al. / IJC Metabolic & Endocrine 9 (2015) 31–38groups were combined in order to evaluate the capability of identiﬁed
metabolic ﬁngerprint to predict cardiovascular events. Finally, a third
independent groupwas proﬁled as “event-replication” group. Twoprin-
cipal component analysis-derived factors resulted associated with CAD:
the ﬁrst comprised branched-chain amino acid metabolites, and the
second consisted of urea cycle metabolites. Furthermore, a factor com-
posed of dicarboxylacylcarnitines was able to predict death/myocardial
infarction and resulted associated with CV events in the third group
[38].
Two years later, the same Shah published another study based on
MS proﬁling of 69metabolites of 2.023 consecutive patients undergoing
cardiac catheterization. Statistical analysis of metabolomics data was
conducted using PCA, whereas independent relationships between
factors and time-to-clinical events were assessed using Cox modeling.
Subsequently, clinical and metabolomic models were compared. Five
of 13 metabolite factors were independently associated with mortality
(medium-chain acylcarnitines, short-chain dicarboxylacylcarnitine,
long-chain dicarboxylacylcarnitines, branched-chain amino acids and
fatty acids), and three were associated with death/MI (factors 2, 3 and
12). In detail, 27% and 11% of the intermediate-risk patients were cor-
rectly reclassiﬁed in terms of mortality and death/MI, respectively [39].
More recently, Rizza and coll., with the aim to create an integrated
clinical-metabolomic model able to improve the prediction of incident
CV events in aged people, performed a targeted MS-based proﬁling of
49 metabolites in a group of very elderly patients (n = 67, mean age
of 85 ± 3 years) with previous cardiovascular diseases and showed
that mitochondrial dysfunction detected by metabolomic analysis was
associated with MACEs after adjustment for clinical CV covariates. The
two metabolites that were independently associated with cardiac com-
plications were medium/long-chain acylcarnitines and alanine. More-
over, when compared with the Framingham Recurring-Coronary-
Heart-Disease-Score, medium/long-chain acylcarnitines showed to
determine a signiﬁcant improvement in discrimination with a cNRI
(Net Reclassiﬁcation Improvement) = 0.79 [40].
Despite establishment of secondary prevention strategies and the
advent of increasing technology coronary stents, restenosis after stent
implantation remains amajor topic in cardiology.With this background,
Hasokawa and coll. conducted in 2012 a study on 86 patients whowere
hospitalized for a 6-month follow-up coronary angiography after stent
implantation (23 with major restenotic lesions, 47 with minor
restenotic lesions and 16with de novo atherosclerotic lesions), identify-
ing a cluster of 8 metabolites - isobutylamine, sarcosine, homoserine,
ribulose, taurine, glutamine, glucose, and tryptophan - that were signif-
icantly different in patients with major restenosis in comparison with
those with minor restenosis [41].
Interesting ﬁndings about ischemia-induced metabolic derange-
ments derive from a study of Turer and coll. in the setting of cardiac sur-
gery. An MS-based platform was applied to proﬁle 63 intermediate
metabolites in blood obtained from serial paired peripheral arterial
and coronary sinus of 37 patients undergoing cardiac surgery. After re-
perfusion, metabolomics proﬁling revealed distinct patterns of myocar-
dial substrate utilization, with signiﬁcant differences between patients
with andwithout CAD. In particular, signiﬁcantly lower extraction ratios
of most substrates, as well as the signiﬁcant release of 2 speciﬁc
acylcarnitine species; moreover, these alterations were more evident
in patients with impaired ventricular function, suggesting limited
myocardial metabolic reserve and ﬂexibility in this group of patients.
Over the physiopathologic issues, authors highlighted that alterations
in metabolic proﬁles after ischemia/reperfusion are associated with
postoperative hemodynamic course and could have a role in role for
optimization of perioperative care of cardiac surgical patients [42].
1.5.4. Arrhythmias
Atrial ﬁbrillation (AF) is the most common arrhythmia in clinical
practice. Despite similar CV risk factors, different proportion of patients
with paroxysmal AF develops persistent or permanent AF.Combined metabolomic and proteomic analyses were used to eval-
uate whether metabolic derangements might “modulate” the progres-
sion of AF. The contribution of electrical, structural, and contractile
remodeling processes to the self-perpetuating nature of this arrhythmia
is nowwell known. However, the role of metabolic changes in themyo-
cardium has only been partially investigated. High-resolution proton
NMR spectroscopywas used to analyze human atrial appendage tissues
from matched cohorts of patients undergoing cardiac surgery in sinus
rhythm, in persistent atrial ﬁbrillation o who developed AF post-
operatively [43]. The persistent AF patients presented a rise in beta-
hydroxybutyrate, the major substrate in ketone body metabolism,
along with an increase in ketogenic amino acids and glycine. These
metabolomic ﬁndings were substantiated by proteomic experiments
demonstrating the differential expression of 3-oxoacid transferase, the
key enzyme in ketolytic energy production. Noteworthy, patients sus-
ceptible to post-operative AF showed a deregulation of energy metabo-
lites in comparison with patients in sinus rhythm and may be correctly
identiﬁed using metabolic proﬁle in more than 80% of cases.
1.5.5. Pediatric cardiology
A small minority of metabolomic investigations have been devoted
to cardiovascular risk factors and diseases in pediatric patients [44].
However, an unfavorable perinatal environment (maternal diseases
such as diabetes, placental insufﬁciency, malnutrition, among others)
may adversely affect the future evolution and function of the cardiovas-
cular system, although adverse events may not occur until adulthood
[45]. In addition, cardiac and renals function appear to be increasingly
interdependent, and renal dysfunction in preterm or underweight in-
fants can predict future CV events [46,47]. Metabolomic analysis of
urine samples was performed in 40 children who underwent cardiac
surgery for correction of congenital cardiac defects [48]. Homovanillic
acid sulfate, a dopamine metabolite, was able to discriminate patients
who developed acute kidney injury from those who did not and was
proposed as a new, sensitive, and predictive early biomarker of kidney
injury. Moreover, a metabolic signature for patent ductus arteriosus in
preterm infants was identiﬁed using NMR-based metabolomic analysis
of urine samples [49].
Recently, our group published a study of young adults who were
born preterm with extremely low birth weights (b1000 g; ex-ELBW;
n = 19) compared with a control group of subjects who were born at
term with a weight appropriate for their gestational age (AGA; n =
13) to evaluate the presence of differences in the urinarymetabolic pro-
ﬁle and in the hematic asymmetric dimethylarginine (ADMA) level. To
achieve this goal, urine samples were analyzed by NMR spectroscopy,
and then submitted to an unsupervised and a supervised multivariate
analysis. Blood samples were collected, and the ADMA concentration
was assessed with high-performance liquid chromatography. Using a
PLS-DA model, it was possible to discriminate between ex-ELBW and
AGA. Statistically signiﬁcant differences in ADMA levels were detected
between ex-ELBW and AGA. Moreover, the metabolic proﬁle correlated
with the ADMA concentrations in ex-ELBW but not in AGA, thus
suggesting the presence of a subclinical cardio-renal impairment in
ex-ELBW subjects [47].
1.5.6. Heart failure
Heart failure (HF) is characterized by metabolic remodeling and an
increasing number of studies highlights the importance of the impair-
ment in cardiac energymetabolism in the progression ofHF [50]. During
this metabolic remodeling, changes in substrate utilization, oxidative
phosphorylation, and high-energy phosphate metabolism occur.
Althoughmetabolomics has had a substantial impact on the investi-
gation of various cardiovascular diseases [3,4], recent published studies
on its application in HF has produced conﬂicting results.
The ﬁrst study addressed to apply metabolimics to heart failure has
been published in 2011 by Kang and coll. who carried out an NMR-
based proﬁling on urine of 15 HF patients and 20 healthy subjects. The
37M. Deidda et al. / IJC Metabolic & Endocrine 9 (2015) 31–38results, obtained with the application of an OPLS-DA, showed higher
urinary levels of acetate, acetone, cytosine, methylmalonate and
phenylacetylglycine and decreased of 1-methylnicotinamide in HF pa-
tients compared to the healthy controls. These ﬁndings suggest that
Krebs cycle metabolites and fatty acid metabolism were modiﬁed dur-
ing HF, conﬁrming an altered energy metabolism in these patients [51].
In 2013, Tenori and coll. conducted an NMR-based study consider-
ing, in addition to the presence of HF, its relationship with BNP and
the NYHA classes. To this aim they enrolled 185 patients with stable
chronic HF and under a state-of-the-art therapy, whereas 111 age and
sex matched healthy subjects constituted the control group. After ap-
plying an OPLS-DA, they concluded that the metabolism in HF patients
shows a disease-related proﬁle in comparison with healthy subjects
(higher serum concentrations of phenylalanine, tyrosine, isoleucine,
and creatine, and lower levels of serum lactate, citrate, lysine and
L-dopa), behaving like an on/off phenomenon regardless of the severity
of the disease [52].
In contrast, Du and coll. found that the serum metabolite proﬁles of
patients with different degrees of systolic dysfunction were associated
with a progressive impairment of myocardial energy expenditure
(MEE), a parameter that is related to the left ventricular ejection fraction
(LVEF). Accordingly, based on theMEE levels, the study population was
classiﬁed into three groups with progressive disease severity. Each
group was characterized by a speciﬁc metabolic ﬁngerprint, which
was obtained after the Orthogonal Signal Correction and PLS regression
analysis. The Variable Important in Prediction (VIP) related to increased
levels of MEE were 3-hydroxybutyrate, acetone and succinate [53]. Un-
fortunately, the MEE as well as all of the parameters derived from re-
gional and global LV functions were not very sensitive because they
were highly dependent on loading and likely to produce abnormal re-
sults if they were obtained under unusual load conditions as in HF [54].
On the other hand, the group of Padeletti carried out a prospective
study in which were collected blood and urine samples from 32 HF pa-
tients who underwent cardiac resynchronization therapy (CRT) and
from 39 age and sex-matched healthy subjects. Clinical, electrocardiog-
raphy and echocardiographic evaluations were performed in each
patient before CRT and after 6 months of follow-up (6FU). The
metabolomic analysis demonstrated a different metabolic ﬁngerprint
in HF patients compared to healthy controls, both at enrollment and at
6FU. It is noteworthy that the 6FU metabolic ﬁngerprint was different
from the baseline ﬁngerprint, independent of the different causes of
the disease, but was not predictive of the response to CRT [55].
More recently, a key study aimed to assess the diagnostic and prog-
nostic values of metabolomics in HF was published by Cheng and coll.;
they performed a mass spectrometry-based proﬁling of plasma metab-
olites in over 400 HF patients and 114 control subjects, divided in two
groups, the ﬁrst used in order to build a metabolomic model of the dis-
ease and identify the relative metabolic ﬁngerprint, the second for the
validation of the model. Moreover a third, independent group of Class
C HF patients who showed a recovery to the I NHYA class at 6 and 12
months follow-up was enrolled and analyzed. A ﬁngerprint constituted
by histidine, phenylalanine, spermidine, and phosphatidylcholine
C34:4, showed to have a diagnostic value comparable to BNP. Further-
more, when prognostic value was evaluated using the combined
endpoints of death or HF-related re-hospitalization, a metabolite
panel, which included asymmetric methylarginine/arginine ratio,
butyrylcarnitine, spermidine, and the total amount of essential amino
acids, was identiﬁed and its prognostic values resulted independent of
BNP and traditional risk factors and was better than that of BNP [56].
Our preliminary data seem to conﬁrm that metabolomics is able to
differentiate HF patients with different degrees of systolic dysfunction
using the Speckle Tracking-derived longitudinal Strain Rate as the Y
variable in amultivariate analysis. The PLS-DA showed a clear clustering
of three a priori classes (LVEF b35%, LVEF N35% and b50%, healthy sub-
jects), with a progressive modiﬁcation of the metabolic ﬁngerprint of
healthy subjects towardsHF patientswith severe impairment of systolicfunction; the most important metabolites implicated in the clustering
were 2-hydroxybutyrate, glycine, methylmalonate, and myo-inositol
[57].2. Conclusions
Cardiovascular diseases are the leading cause of death worldwide.
However, their molecular etiology and pathophysiological progression
remain incompletely understood, probably because they result from
both genetic and environmental factors; for this reason, the systembiol-
ogy approach, that consider each biologic event as a part of a complex
network of interactions, could be the way to dramatically improve our
knowledge of mechanism that underlie the development of disease
status. In fact, one of the challenges of translational research is exact-
ly to integrate, in a holistic approach, clinical data with proteomic,
transcriptomic and metabolomic information.
In this regard, the sensitivity shown by metabolomics in the detec-
tion of molecular changes resulting from physical-pathological process-
es “proximal” to the disease could represent a great opportunity.
The success of this approach will depend on how the different data
will be integrated, as exempliﬁed in presented studies. Finally, the asso-
ciation of metabolomics – and all the “omics” sciences – with clinical
and instrumental data could improve our understanding of themolecu-
lar basis of cardiovascular diseases, prediction of therapeutic responses
and risk of adverse effects during treatment, and ﬁnal implementation
of new tools towards the goal of more personalized medicine.References
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